Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 2/20 | 0.57 |
| ▸ | INSR | P06213 | 10/20 | 0.52 |
| ▸ | LCK | P06239 | 10/20 | 0.52 |
| ▸ | LYN | P07948 | 10/20 | 0.52 |
| ▸ | SRC | P12931 | 10/20 | 0.52 |
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | HCK | P08631 | 10/20 | 0.52 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822577 | 0.93 | LYN (0.51) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL3234488 | 0.93 | CSF1R (0.60) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL1824003 | 0.91 | INSR (0.60) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL13269773 | 0.89 | LYN (0.62) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL1826484 | 0.87 | NR2C2 (0.58) | HCKNR2C2BRAF | |
| SCHEMBL17470236 | 0.87 | HCK (0.48) | INSRLCKLYNSRCKDR | |
| SCHEMBL1824820 | 0.86 | CSF1R (0.42) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL3234828 | 0.86 | NR2C2 (0.59) | HCKNR2C2BRAF | |
| SCHEMBL1824965 | 0.86 | LYN (0.58) | CSF1RINSRLCKLYNSRC | |
| SCHEMBL13269782 | 0.85 | LYN (0.56) | CSF1RINSRLCKLYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-7745437-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-06-29 | — | — | US | disclosed |
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225286-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, PTK2B, SRC | CSF1R 1032/4885INSR 2395/4885LCK 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.